Compare MSS & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | VIVS |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.9M |
| IPO Year | 2023 | N/A |
| Metric | MSS | VIVS |
|---|---|---|
| Price | $0.15 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 67.9K |
| Earning Date | 03-17-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,217,480.00 | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | $7.09 | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.01 | N/A |
| 52 Week Low | $0.13 | $1.42 |
| 52 Week High | $3.96 | $5.30 |
| Indicator | MSS | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 29.62 | 36.99 |
| Support Level | $0.13 | N/A |
| Resistance Level | $0.31 | $2.31 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 7.30 | 13.41 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.